The Impact of Extended Typing On Red Blood Cell Alloimmunization in Transfused Patients
DOI:
https://doi.org/10.3889/oamjms.2017.054Keywords:
ABO/RH typing, RBC alloantibodies, RBC transfusionAbstract
BACKGROUND: Red blood cell (RBC) alloimmunization is still an actual problem in our transfusion practice. In 2011, in addition to the regular ABO/D blood group typing, phenotyping for Rh (C, c, E, e) and Kell antigens was introduced for blood donors and patients undergoing blood transfusion. Our aim was to evaluate the impact of the extended RBC typing and donor/recipient matching on the incidence of RBC alloimmunization.
METHODS: A retrospective comparative study was conducted by reviewing RBC request records for about 36,000 patients transfused with RBC in the period from 2013 to 2015 in comparison to the similar study conducted on 47,000 transfused patients in the period from 2005 to 2008. Pre-transfusion serologic testing data were retrieved for analysis. Blood samples with positive antibody screening and positive cross-match were further subjected to antibody identification. All the tests were performed using column agglutination technique (CAT) with ID-cards and reagents from DiaMed in both studies.
RESULTS: Irregular RBC alloantibodies were detected in 116 (0.32%) out of 36,000 transfused patients. Multiple transfusions (15.8 units/patient) were given to 450 patients from which 79 (17.5%) had RBC allontibodies. The incidence of RBC alloimmunisation in the rest of the 35,550 transfused patients from which 37 had RBC alloantibodies was 0.10%. A total of 117 alloantibodies were identified in 96 out of the 116 patients with irregular RBC antibodies. Their specificity was as fallows: anti-E (25.6%), -C (6.0%), -c (8.5%), -e (0.85%), -Cw (5.1%), -K (12.8%), -Fya (10.2%), -Fyb ( 2.5%), -Jka (7.7%), -Jkb (2.5%), -M (9.4%), -S (1.7%), -s (0.85%), -Lua (1.7%), -Leb (3.4%) and anti-Leb (0.85%). Multiple antibodies were identified in 22 of the transfused patients out of which 15 (68.2%) received multiple transfusions. Anti-E was the most common antibody found in more of the 50% of the multiple antibody cases.
CONCLUSIONS: The overall incidence of RBC alloimmunization in transfused patients decreased from 0.51% which was the estimated incidence for the period before the introduction of the extended RBC typing (2005-2008) to 0.32% (2013-2015). This is due to the decreased incidence of RBC alloimmunization in the multiply transfused patients from 33.9% to 17.5% respectively. The current frequency of anti-E (25.6%) and -K (12.8%) antibodies in transfused patients are significantly lower than their previous estimated frequencies of 30.4% and 24.0% respectively, as well as the overall frequency of RBC antibodies to Rh+Kell antigens which decreased from 72.4% to 53.8%. Extended donor-recipient matching for C, c, E, e and Kell antigens has proved a beneficial effect on the incidence of RBC alloimmunization in multiply transfused patients.Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Daniels G, Poole J, de Silva M, Callagan T, MacLennan S, Smith N. The clinical significance of blood group antibodies. Transfusion Med. 2002; 12: 287-295. https://doi.org/10.1046/j.1365-3148.2002.00399.x
Flegel WA. Pathogenesis and mechanisms of antibody-mediated hemolysis. Transfusion. 2015; 55(2):47-58. https://doi.org/10.1111/trf.13147 PMid:26174897 PMCid:PMC4503931
Landsteiner K. Ueber Agglutinationserscheinungen normalen menschlichen Blutes. Wien Klin Wochenschr. 1901;14:1132-1134.
Ottenberg R. Studies on isoagglutination. Transfusion and the question of intravascular agglutination. J Exp Med. 1911; 13:425-438. https://doi.org/10.1084/jem.13.4.425
Unger LJ. Precautions necessary in the selection of a donor for blood transfusion. JAMA. 1921; 76:9-11. https://doi.org/10.1001/jama.1921.02630010013003
Poole J, Daniels G. Blood group antibodies and their significance in transfusion medicine. Transfus Med Rev. 2007;21:58–71. https://doi.org/10.1016/j.tmrv.2006.08.003 PMid:17174221
Urbaniak SJ, Robertson AE. A successful program of immunizing Rh-negative volunteers for anti-D production using frozen/thawed blood. Transfusion. 1981;21:64-69. https://doi.org/10.1046/j.1537-2995.1981.21181127486.x
Singerb ST, Wu V, Mignacca R. et al. Alloimmunisation and erythrocyte autoimmunisation in transfusion-dependent thalassemia patients of predominant Asian descent. Blood. 2000; 96(10):3369-3373.
Daniels G, Bromilow I. Essential Gide to Blood Groups. Blackwell publishing, 1st Ed., 2007: 1-5. https://doi.org/10.1002/9780470750926.ch1 PMid:17150014
Hoeltge GA, Domen RE, Rybicki LA, Schaffer PA. Multiple red cell transfusions and alloimmunization. Experiences with 6996 antibodies detected in a total of 159,262 patients from 1985-1993. Arch Pathol Lab Med. 1995;119:42-45. PMid:7802552
Makarovska-Bojadzieva T, Blagoevska M, Kolevski P, Kostovska S. Optimal blood gouping and antibody screenining for safe transfusion. Contributions Sec Biol Med Sci MASA. 2009; 30 (1): 119-128.
Oren E. Alloimmunization from transfusion emedicine medscape com/article/134958.
Bolton-Maggs P, Poles D, Watt A, Cohen H, Thomas D. Serious Hazards of Transfusion (SHOT) haemovigilance and progress is improving transfusion safety. Br J Haematol. 2013; 163(3): 303–314. https://doi.org/10.1111/bjh.12547 PMid:24032719 PMCid:PMC3935404
SHOT Annual Report 2014. Available from: http://www.shotuk.org/wp-content/uploads/ SHOT-2014-Annual-Reportv11-Web-Edition.pdf [Accessed 4 August 2015].
Strobel E. Hemolytic transfusion reactions. Transfus Med Hemother. 2008; 35:346-353. https://doi.org/10.1159/000154811 PMid:21512623 PMCid:PMC3076326
Mazzei CA, Popovsky MA, Kopko PM. Noninfectious complications of blood transfusion. In: Roback JD, Combs MR, Grossman BJ, et al., editors. Technical Manual. 16th Ed. Bethesda, MD: American Association of Blood Banks, 2008: 715–749.
Sanz C, Nomdedeu M, Belkaid M, Martinez I, Nomdedeu B, Pereira A. Red blood cell alloimmunization in transfused patients with myelodysplastic syndrome or chronic myelomonocytic leukemia. Transfusion. 2013; 53(4):710-5. https://doi.org/10.1111/j.1537-2995.2012.03819.x PMid:22845746
Azarkeivan A, Ansari S, Ahmadi MH, Hajibeigy B, Maghsudlu M, Nasizadeh S, Shaigan M, Toolabi A, Salahmand M. Blood transfusion and alloimmunization in patients with thalassemia: multicenter study. Pediatr Hematol Oncol. 2011; 28(6):479-85. https://doi.org/10.3109/08880018.2011.568595 PMid:21854216
Vichinsky EP, Luban NL, Wright E, Olivieri N, Driscoll C, Pegelow CH, Adams RJ. Prospective RBC phenotype matching in a stroke-prevention trial in sickle cell anemia: a multicenter transfusion trial. Transfusion. 2001; 41(9):1086-92. https://doi.org/10.1046/j.1537-2995.2001.41091086.x PMid:11552063
Miller ST, Kim HY, Weiner DL, Wager CG, Gallagher D, Styles LA, Dampier CD, Roseff SD. Red blood cell alloimmunization in sickle cell disease: prevalence in 2010. Transfusion. 2013; 53(4):704-9. https://doi.org/10.1111/j.1537-2995.2012.03796.x PMid:22804353 PMCid:PMC5096391
Cheng CK, Lee CK, Lin CK. Clinically significant red blood cell antibodies in chronically transfused patients: a survey of Chinese thalassemia major patients and literature review. Transfusion. 2012; 52(10):2220-4. https://doi.org/10.1111/j.1537-2995.2012.03570.x PMid:22339270
Schonewille H, van de Watering LM, Brand A. Additional red blood cell alloantibodies after blood transfusions in a nonhematologic alloimmunized patient cohort: is it time to take precautionary measures? Transfusion. 2006; 46(4):630-635. https://doi.org/10.1111/j.1537-2995.2006.00764.x PMid:16584440
Avent ND, Martinez A, Flegel WA, et al. The Bloodgen Project of the European Union, 2003-2009. Transfus Med Hemother. 2009; 36 (3): 162-167. https://doi.org/10.1159/000218192 PMid:21113258 PMCid:PMC2980524
Flegel WA, Gottschal JL, Denomme GA. Implementing mass-scale red cell genotyping at a blood center. Transfusion. 2015;55(11):2610-5. https://doi.org/10.1111/trf.13168 PMid:26094790 PMCid:PMC4644091
Downloads
Published
How to Cite
Issue
Section
License
http://creativecommons.org/licenses/by-nc/4.0
